Christchurch biotech firm PharmaZen – better known as Waitaki Biosciences – has found out the hard way what happens when relations with an investor sour.
As reported in The Bottom Line on Dealmakers over the weekend, the USX-listed firm was late with lodging its financial statements for the calendar 2024 year after getting a redemption notice from European agritech investor Cibus, which injec...
